Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ...
In This Article:
On May 31, 2024, Cam Gallagher, President and Interim Chief Financial Officer of Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL), sold 9,597 shares of the company. The transaction was documented in an SEC Filing. Following this sale, the insider now owns 633,680 shares of Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is focused on the discovery and development of small molecule therapeutics for the treatment of various cancers. The company's approach involves targeted therapies that are designed to address specific pathways or mechanisms that are critical to cancer progression.
Over the past year, the insider has sold a total of 22,322 shares and has not made any purchases. The broader trend in insider transactions for Zentalis Pharmaceuticals Inc shows a pattern of more sales than purchases, with 12 insider sells and only 2 insider buys over the last year.
Shares of Zentalis Pharmaceuticals Inc were priced at $11.98 on the day of the insider's recent transaction. The company has a market cap of approximately $843.637 million.
For further insights into the company's valuation metrics, such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can visit the respective links.
This insider selling activity may be of interest to current and potential investors trying to understand the recent movements in Zentalis Pharmaceuticals Inc's stock and the perspectives of high-level insiders within the company.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.